Knox Ricksen LLP is currently undergoing investigations into claims from individuals who have experienced harmful side effects from the drug Xarelto.
Xarelto (Rivaraxaban) is an anticoagulant drug invented by Bayer and marketed by Janssen Pharmaceuticals; it works by thinning the blood to prevent clotting. In 2011, the FDA approved Xarelto to treat deep vein thrombosis (DVT), reduce the risk of stroke in people with abnormal heart rhythm (non-valvular atrial fibrillation), and reduce the risk of DVT or pulmonary embolism (PE). Since its release warnings have been issued, informing individuals that the use of the drug could lead to damaging side effects. A similar blood thinner, Pradaxa, has seen near to two hundred cases filed from victims that received serious internal bleeding from the drug. Xarelto may be on the same course with a number of deaths linked to the drug in 2012, and with no antidote the side effects can be difficult to reverse.
Rocket Safety Study
The “ROCKET” safety study has been the largest examination of the Xarelto to date. 14,000 patients were used to compare Xarelto and Warfarin. The results showed that Xarelto and Warfarin were about the same in effectiveness, and that the two had similar risks. Bleeding was the most common and comparable side effect of the two drugs, with Xarelto causing less bleeding in the brain and more in the stomach and intestines.
Percentages of Patients who Experience Bleeding